全文获取类型
收费全文 | 1201篇 |
免费 | 91篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 9篇 |
妇产科学 | 15篇 |
基础医学 | 210篇 |
口腔科学 | 106篇 |
临床医学 | 149篇 |
内科学 | 283篇 |
皮肤病学 | 7篇 |
神经病学 | 96篇 |
特种医学 | 37篇 |
外科学 | 166篇 |
综合类 | 6篇 |
预防医学 | 59篇 |
眼科学 | 6篇 |
药学 | 73篇 |
中国医学 | 3篇 |
肿瘤学 | 61篇 |
出版年
2023年 | 6篇 |
2022年 | 25篇 |
2021年 | 46篇 |
2020年 | 24篇 |
2019年 | 41篇 |
2018年 | 37篇 |
2017年 | 16篇 |
2016年 | 32篇 |
2015年 | 34篇 |
2014年 | 53篇 |
2013年 | 65篇 |
2012年 | 89篇 |
2011年 | 103篇 |
2010年 | 58篇 |
2009年 | 44篇 |
2008年 | 93篇 |
2007年 | 89篇 |
2006年 | 91篇 |
2005年 | 76篇 |
2004年 | 68篇 |
2003年 | 58篇 |
2002年 | 39篇 |
2001年 | 12篇 |
2000年 | 10篇 |
1999年 | 8篇 |
1998年 | 13篇 |
1997年 | 8篇 |
1996年 | 10篇 |
1995年 | 7篇 |
1994年 | 5篇 |
1993年 | 4篇 |
1992年 | 1篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 4篇 |
1988年 | 3篇 |
1987年 | 1篇 |
1986年 | 3篇 |
1985年 | 2篇 |
1984年 | 4篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1978年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1974年 | 2篇 |
1967年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有1298条查询结果,搜索用时 15 毫秒
161.
162.
163.
164.
165.
Quantitative insight into proliferation and differentiation of oligodendrocyte type 2 astrocyte progenitor cells in vitro 总被引:2,自引:0,他引:2
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Andrej Y. Yakovlev Kenneth Boucher Margot Mayer-Proschel Mark Noble 《Proceedings of the National Academy of Sciences of the United States of America》1998,95(24):14164-14167
As part of our attempts at understanding fundamental principles that underlie the generation of nondividing terminally differentiated progeny from dividing precursor cells, we have developed approaches to a quantitative analysis of proliferation and differentiation of oligodendrocyte type 2 astrocyte (O-2A) progenitor cells at the clonal level. Owing to extensive previous studies of clonal differentiation in this lineage, O-2A progenitor cells represent an excellent system for such an analysis. Previous studies have resulted in two competing hypotheses; one of them suggests that progenitor cell differentiation is symmetric, the other hypothesis introduces an asymmetric process of differentiation. We propose a general model that incorporates both such extreme hypotheses as special cases. Our analysis of experimental data has shown, however, that neither of these extreme cases completely explains the observed kinetics of O-2A progenitor cell proliferation and oligodendrocyte generation in vitro. Instead, our results indicate that O-2A progenitor cells become competent for differentiation after they complete a certain number of critical mitotic cycles that represent a period of symmetric development. This number varies from clone to clone and may be thought of as a random variable; its probability distribution was estimated from experimental data. Those O-2A cells that have undergone the critical divisions then may differentiate into an oligodendrocyte in each of the subsequent mitotic cycles with a certain probability, thereby exhibiting the asymmetric type of differentiation. 相似文献
166.
Radiation-related damage to dentition 总被引:2,自引:0,他引:2
Because of typical tissue reactions to ionising radiation, radiotherapy in the head and neck region usually results in complex oral complications affecting the salivary glands, oral mucosa, bone, masticatory musculature, and dentition. When the oral cavity and salivary glands are exposed to high doses of radiation, clinical consequences including hyposalivation, mucositis, taste loss, trismus, and osteoradionecrosis should be regarded as the most common side-effects. Mucositis and taste loss are reversible consequences, usually subsiding early post-irradiation, whereas hyposalivation is commonly irreversible. Additionally, the risk of rampant tooth decay with its sudden onset and osteonecrosis is a lifelong threat. Thus, early, active participation of the dental profession in the development of preventive and therapeutic strategies, and in the education and rehabilitation of patients is paramount in consideration of quality-of-life issues during and after radiotherapy. This Review focuses on the multifactorial causes of so-called radiation caries and presents possible treatment strategies to avoid loss of dentition. 相似文献
167.
The pathogenesis of implant-associated infection involves interaction between the microorganisms (biofilm formation), the implant and the host. Despite improvement of perioperative prophylaxis, orthopaedic implants still remain highly susceptible to bacterial or fungal contamination, generally resulting in persistent implant-associated infection. Therefore, perioperative and life-long prevention of infection is important. For perioperative prophylaxis, a first- or second-generation cephalosporin is recommended, which should be administered between 60 and 30 minutes before incision. The duration of prophylaxis should not exceed 1 day. In centres with a low incidence of infection, a single dose is sufficient. Treatment of infections associated with orthopaedic devices usually requires appropriate surgical intervention combined with prolonged antimicrobial therapy. The choice of the antimicrobial regimen depends on the duration and pathogenesis of infection, stability of the implant, antimicrobial susceptibility of the pathogen and condition of the surrounding soft tissue. The role of rifampicin (rifampin), which has excellent activity on adherent staphylococci, in combination with beta-lactams, glycopeptides, fluoroquinolones, minocycline, cotrimoxazole or fusidic acid, in the treatment of staphylococcal infections is outlined. Increasing antimicrobial resistance requires the use of alternative agents, such as quinupristin/dalfopristin, linezolid and daptomycin, but results of clinical trials with these agents are limited. Also reviewed are potential new antimicrobial agents currently undergoing investigation, such as the novel oxazolidinone RWJ-416457, the new glycopeptide dalbavancin, the glycylcycline compound tigecycline, the new carbacephem BP-102 and novel rifamycin derivatives. Vaccination against Staphylococcus aureus with StaphVAX induced specific antibodies potentially preventing bacteraemia; however, there are no studies on efficacy in the prophylaxis of device-associated infections with this vaccine. 相似文献
168.
169.
PURPOSE: To describe the occurrence and heritability of astigmatism in a population-based sample of Norwegian twins. METHODS: Self-reported history of astigmatism based on questionnaire responses was used to estimate the prevalence and incidence rates of astigmatism from birth through 31 years in 8,045 twins. Kaplan-Meier analysis and log-binomial regression were used to study the conditional and relative risk of astigmatism in twin pairs by sex and zygosity. Tetrachoric correlations and structural equation models were applied to estimate the genetic and environmental sources of variations in liability for astigmatism. RESULTS: Altogether 21.1% of males and 29.3% of females (p < 0.001) reported a positive history of astigmatism. Estimated incidence rates peaked in both sexes in the group aged 16-19 years and then decreased. Both conditional and relative risks of developing astigmatism were considerably higher in monozygotic than in dizygotic twins if a cotwin reported a positive history of astigmatism. The best-fitting biometrical model suggested that additive genetic, dominant genetic, and individual environmental effects explained 9% (95% CI: 0-40), 54% (95% CI: 20-69), and 38% (95% CI: 31-45) of the variation in the liability to astigmatism, respectively. No differences in heritability of astigmatism between the genders were found. CONCLUSIONS: The prevalence of self-reported astigmatism in twins is comparable with previous findings from Norway. Our results suggest considerable genetic contribution to the development of astigmatism in young adult Norwegian twins mainly due to dominant genetic effects, which are similar in both males and females. 相似文献
170.
The clinical pharmacokinetics of darifenacin 总被引:2,自引:0,他引:2
Skerjanec A 《Clinical pharmacokinetics》2006,45(4):325-350
Darifenacin hydrobromide is a selective muscarinic M(3) receptor antagonist that is indicated for use in treatment of overactive bladder disorder. Darifenacin was found to have a short terminal elimination half-life after intravenous and immediate-release oral dosage forms (3-4 hours) but this increased with a prolonged-release (PR) formulation (14-16 hours). The absolute bioavailability of darifenacin from 7.5 and 15 mg PR tablets was estimated to be 15.4% and 18.6%, respectively. With repeated once-daily oral administration of the PR formulation, peak plasma concentrations of darifenacin are achieved approximately 7 hours post-dose. After oral administration, darifenacin is well absorbed from the gastrointestinal tract and very little unchanged drug (<2%) is recovered in the faeces. Steady state is achieved after 6 days of once-daily administration of the PR formulation. As expected, values of peak plasma concentration (C(max)) and area under the plasma concentration-time curve are dose dependent, although the increase in plasma concentrations is proportionally greater than the increase in dose owing to saturation of presystemic metabolism. From intravenous administration, it has been established that darifenacin possesses a moderate-to-high hepatic extraction ratio, with high plasma clearance (36-52 L/h) and a volume of distribution (165-276L) that exceeds total body water. It is highly protein bound (98%), primarily to alpha(1)-acid glycoprotein. Darifenacin is subject to extensive hepatic metabolism, with 3% of unchanged drug excreted in urine and faeces. Metabolism is mediated by hepatic cytochrome P450 2D6 and 3A4, the main metabolic routes being monohydroxylation in the dihydrobenzfuran ring, dihydrobenzfuran ring opening, and N-dealkylation of the pyrrolidine nitrogen. Several possibly important drug-drug interactions have been identified with darifenacin, including ketoconazole, erythromycin and fluconazole, each of which increases darifenacin mean C(max) by 9.52-, 2.28- and 1.88-fold, respectively. When given with imipramine, darifenacin causes 1.6-fold higher plasma concentrations of the antidepressant and its major metabolite. Moderate hepatic impairment, but not renal insufficiency, has been shown to increase plasma concentrations of the drug. The pharmacokinetic profile of darifenacin is not affected by food. 相似文献